[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-001", "question": "A 56-year-old man with long-standing type 2 diabetes, CKD stage 3b, and prior NSTEMI presents for routine follow-up. Medications: metformin 500 mg BID, empagliflozin 10 mg daily, lisinopril 20 mg daily, metoprolol succinate 100 mg daily, and high-intensity statin. BP is 118/66 mm Hg, BMI 31 kg/m², A1c 7.2%. eGFR is 37 mL/min/1.73 m², urinary ACR 620 mg/g (persistent over 9 months), potassium 4.6 mEq/L. He has no hyperkalemia history. Which change in therapy is most appropriate to further reduce his cardiorenal risk?", "options": ["Increase empagliflozin to 25 mg daily", "Add finerenone with close potassium monitoring", "Replace lisinopril with sacubitril/valsartan", "Add basal insulin to target A1c <6.5%", "Add a non-dihydropyridine calcium channel blocker"], "answer": "B", "answer_index": 1, "explanation": "Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces CV events and CKD progression in diabetics with albuminuric CKD already on ACEi/ARB and SGLT2i and with eGFR >25 and K<4.8. Increasing SGLT2 dose adds minimal incremental renal protection, sacubitril/valsartan is not indicated without HFrEF, tighter glycemic control adds little cardiorenal benefit with more risk, and non-DHP CCBs do not provide proven outcome benefit here.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 56-year-old with T2DM, CKD stage 3b (eGFR 37), persistent albuminuria (ACR 620 mg/g), prior NSTEMI, on metformin, empagliflozin 10 mg, lisinopril, metoprolol, statin; BP controlled at 118/66, A1c 7.2%, K 4.6 without hyperkalemia history. These support adding finerenone per FIDELIO-DKD trial criteria for cardiorenal protection in albuminuric DKD on ACEi/ARB and SGLT2i, with eGFR >25 and K <4.8. Main logical issue(s): None; stem provides sufficient details for discrimination without contradictions or underspecification, allowing B as uniquely best. Alternatives are inferior: A offers minimal incremental renal benefit; C requires HFrEF (absent); D risks hypoglycemia with limited cardiorenal gains; E lacks proven outcomes despite controlled BP. Main medical accuracy issue(s): None; aligns with KDIGO/ADA guidelines on nonsteroidal MRA for high-risk DKD, accurate pathophysiology, and modern standards without errors or outdated elements. Minimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 56-year-old with T2DM, CKD stage 3b (eGFR 37), persistent albuminuria (ACR 620 mg/g), prior NSTEMI, on metformin, empagliflozin 10 mg, lisinopril, metoprolol, statin; BP controlled at 118/66, A1c 7.2%, K 4.6 without hyperkalemia history. These support adding finerenone per FIDELIO-DKD trial criteria for cardiorenal protection in albuminuric DKD on ACEi/ARB and SGLT2i, with eGFR >25 and K <4.8. Main logical issue(s): None; stem provides sufficient details for discrimination without contradictions or underspecification, allowing B as uniquely best. Alternatives are inferior: A offers minimal incremental renal benefit; C requires HFrEF (absent); D risks hypoglycemia with limited cardiorenal gains; E lacks proven outcomes despite controlled BP. Main medical accuracy issue(s): None; aligns with KDIGO/ADA guidelines on nonsteroidal MRA for high-risk DKD, accurate pathophysiology, and modern standards without errors or outdated elements. Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-002", "question": "A 4-year-old boy is brought to the ED with 2 days of fever, abdominal pain, and vomiting. PMH includes Kawasaki disease at 11 months treated with IVIG and aspirin; echocardiography then showed a 7-mm giant aneurysm of the left anterior descending coronary artery, which has since regressed to normal dimensions by age 3. He is off antiplatelets and asymptomatic at baseline. Current vitals: T 39.2°C, HR 145/min, BP 82/48 mm Hg, RR 30/min, SpO2 95% RA. He appears ill and mottled with cool extremities. ECG shows sinus tachycardia with ST-segment depression in V4-V6. High-sensitivity troponin is mildly elevated. Bedside echo shows mild global LV dysfunction (EF 45%), no visible aneurysm. After fluid resuscitation and initiation of broad-spectrum antibiotics, which management step is most appropriate now?", "options": ["Re-treat with high-dose IVIG and start high-dose aspirin", "Obtain emergent coronary CT angiography and start IV heparin", "Start IV milrinone and low-dose aspirin without additional imaging", "Start IV methylprednisolone plus IVIG and transfer for ECMO standby", "Begin norepinephrine for septic shock and defer cardiac-specific therapy"], "answer": "B", "answer_index": 1, "explanation": "Children with prior giant Kawasaki aneurysms remain at risk for thrombosis and stenosis despite angiographic regression; acute coronary syndrome can mimic sepsis. ST depression, hypotension, and troponin elevation warrant urgent coronary imaging (CT angiography) and antithrombotic therapy. Routine retreatment with IVIG is not indicated years later, steroids/ECMO are premature without refractory shock, and treating as isolated sepsis risks missing coronary occlusion.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: History of Kawasaki disease with giant coronary aneurysm (regressed but prior risk persists); current fever, abdominal pain, vomiting, hypotension, mottled extremities, ST-segment depression in V4-V6, mildly elevated troponin, and mild LV dysfunction (EF 45%) despite fluid resuscitation and antibiotics—suggesting possible acute coronary syndrome mimicking or complicating sepsis, warranting urgent coronary evaluation and antithrombosis over routine KD retreatment or isolated shock management.\\nMain logical issue(s), if any: None; the vignette provides sufficient discriminating findings (cardiac biomarkers, ECG changes, echo dysfunction, and KD history) to identify B as uniquely best without contradictions or underspecification, as alternatives either ignore coronary risk (E), inadequately address it without imaging (C), or apply inappropriate acute KD therapies (A, D).\\nMain medical accuracy issue(s), if any: None; aligns with AHA guidelines on long-term KD management, recognizing thrombosis/stenosis risk post-giant aneurysm regression; ACS presentation can overlap with sepsis in children, justifying emergent CT angiography and heparin initiation while covering infection.\\nMinimal fix: No fix needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: History of Kawasaki disease with giant coronary aneurysm (regressed but prior risk persists); current fever, abdominal pain, vomiting, hypotension, mottled extremities, ST-segment depression in V4-V6, mildly elevated troponin, and mild LV dysfunction (EF 45%) despite fluid resuscitation and antibiotics—suggesting possible acute coronary syndrome mimicking or complicating sepsis, warranting urgent coronary evaluation and antithrombosis over routine KD retreatment or isolated shock management.\nMain logical issue(s), if any: None; the vignette provides sufficient discriminating findings (cardiac biomarkers, ECG changes, echo dysfunction, and KD history) to identify B as uniquely best without contradictions or underspecification, as alternatives either ignore coronary risk (E), inadequately address it without imaging (C), or apply inappropriate acute KD therapies (A, D).\nMain medical accuracy issue(s), if any: None; aligns with AHA guidelines on long-term KD management, recognizing thrombosis/stenosis risk post-giant aneurysm regression; ACS presentation can overlap with sepsis in children, justifying emergent CT angiography and heparin initiation while covering infection.\nMinimal fix: No fix needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-003", "question": "A 32-year-old woman presents with 3 weeks of migratory polyarthritis, pleuritic chest pain, and low-grade fever. Exam: malar rash sparing nasolabial folds, small bilateral pleural effusions, and mild synovitis of wrists and MCPs. Labs: Hb 10.4 g/dL, platelets 145,000/µL, WBC 3,200/µL, Cr 0.8 mg/dL, urine protein/Cr ratio 0.2, AST/ALT mildly elevated. ESR 75 mm/h, CRP 2.1 mg/dL. ANA 1:640 homogeneous, anti-dsDNA high, low C3/C4. Anti-phospholipid antibodies are negative on two occasions 12 weeks apart. Echocardiogram shows a small pericardial effusion without tamponade. She has a confirmed positive pregnancy test at 6 weeks gestation. Which of the following is the most appropriate initial treatment strategy?", "options": ["Start high-dose prednisone plus mycophenolate mofetil", "Start hydroxychloroquine and low-moderate dose prednisone", "Start methotrexate and high-dose NSAIDs", "Defer immunosuppression and treat with low-dose aspirin alone", "Start belimumab and discontinue hydroxychloroquine once controlled"], "answer": "B", "answer_index": 1, "explanation": "This is new-onset SLE with non-organ-threatening disease in early pregnancy; hydroxychloroquine is recommended in all pregnant SLE patients and improves maternal and fetal outcomes. Low-moderate dose prednisone addresses serositis and arthritis with acceptable fetal safety. Mycophenolate and methotrexate are teratogenic, aspirin alone is inadequate for active disease, and belimumab is not first-line in new, non-severe SLE in pregnancy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include new-onset SLE features (malar rash, polyarthritis, serositis, fever, positive ANA/anti-dsDNA, low complements), early pregnancy (6 weeks), non-organ-threatening manifestations (mild synovitis, small effusions without tamponade, no nephritis), and negative anti-phospholipid antibodies. These support initial therapy prioritizing fetal safety and disease control, making hydroxychloroquine (HCQ) plus low-moderate prednisone the best choice, as HCQ is recommended for all pregnant SLE patients to improve outcomes, and low-dose steroids manage serositis/arthritis safely. Alternatives are inferior: A involves teratogenic mycophenolate; C uses teratogenic methotrexate and NSAIDs with pregnancy risks; D inadequately addresses active disease; E positions belimumab (not first-line) and wrongly discontinues HCQ. No main logical issues; the item is coherent, with options allowing clear discrimination without contradictions or underspecification. No main medical accuracy issues; aligns with current ACR/EULAR guidelines for SLE in pregnancy, emphasizing HCQ continuation and avoiding teratogens like mycophenolate/methotrexate. Minimal fix: None needed, as the item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include new-onset SLE features (malar rash, polyarthritis, serositis, fever, positive ANA/anti-dsDNA, low complements), early pregnancy (6 weeks), non-organ-threatening manifestations (mild synovitis, small effusions without tamponade, no nephritis), and negative anti-phospholipid antibodies. These support initial therapy prioritizing fetal safety and disease control, making hydroxychloroquine (HCQ) plus low-moderate prednisone the best choice, as HCQ is recommended for all pregnant SLE patients to improve outcomes, and low-dose steroids manage serositis/arthritis safely. Alternatives are inferior: A involves teratogenic mycophenolate; C uses teratogenic methotrexate and NSAIDs with pregnancy risks; D inadequately addresses active disease; E positions belimumab (not first-line) and wrongly discontinues HCQ. No main logical issues; the item is coherent, with options allowing clear discrimination without contradictions or underspecification. No main medical accuracy issues; aligns with current ACR/EULAR guidelines for SLE in pregnancy, emphasizing HCQ continuation and avoiding teratogens like mycophenolate/methotrexate. Minimal fix: None needed, as the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-004", "question": "A 61-year-old man with obesity and hypertension presents with exertional dyspnea and occasional chest tightness. Resting ECG is normal. Transthoracic echocardiogram shows EF 60%, mild concentric LVH, and no valvular disease. He undergoes a standard exercise treadmill test using Bruce protocol. At stage 3, he develops 2-mm horizontal ST depression in leads V4-V6 and II, III, aVF with peak HR 142/min (89% of predicted). He has no chest pain and BP rises appropriately. Nuclear perfusion imaging done concurrently shows normal perfusion and normal LV function at rest and stress. Coronary CT angiography reveals a short left main with separate LAD and LCx ostia, no atherosclerotic plaque, and a myocardial bridge in the mid-LAD with 80% systolic compression but preserved diastolic lumen. Which is the best next step in management?", "options": ["Start high-dose beta-blocker therapy and avoid further ischemic workup", "Refer for percutaneous coronary intervention with stenting of the bridged segment", "Order invasive coronary angiography with pressure-wire assessment during dobutamine stress", "Schedule surgical myotomy of the myocardial bridge", "Reassure the patient and no further follow-up is required"], "answer": "C", "answer_index": 2, "explanation": "The discordance between ischemic ST changes and normal perfusion imaging in the setting of a significant myocardial bridge raises concern for dynamic flow limitation, especially at higher heart rates not reached on standard testing. Invasive angiography with physiologic assessment (FFR/iFR or diastolic FFR during inotropic stress) clarifies hemodynamic significance and guides need for intensified medical or surgical therapy. Empiric high-dose beta-blockers or surgery without confirming significance is premature, and PCI in bridged segments has high complication rates.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Exertional dyspnea and chest tightness in a 61-year-old with obesity and hypertension; ischemic ST depression on exercise treadmill test at 89% predicted HR without chest pain; normal nuclear perfusion at rest and stress; CCTA showing myocardial bridge in mid-LAD with 80% systolic compression but preserved diastolic lumen and no plaque. These suggest potential dynamic ischemia from the bridge, discordant with normal perfusion, warranting physiologic confirmation.\\nMain logical issue(s), if any: None; the vignette provides sufficient details to discriminate C as the unique best next step for assessing hemodynamic significance without assuming unstated facts.\\nMain medical accuracy issue(s), if any: None; aligns with current standards where myocardial bridges can cause ischemia despite normal perfusion if flow limitation is rate-dependent, and invasive angiography with stress physiologic testing (e.g., dobutamine FFR) is recommended to guide management per cardiology guidelines, avoiding premature interventions like empiric beta-blockers, PCI (high complication risk in bridges), or surgery.\\nMinimal fix: No fix needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Exertional dyspnea and chest tightness in a 61-year-old with obesity and hypertension; ischemic ST depression on exercise treadmill test at 89% predicted HR without chest pain; normal nuclear perfusion at rest and stress; CCTA showing myocardial bridge in mid-LAD with 80% systolic compression but preserved diastolic lumen and no plaque. These suggest potential dynamic ischemia from the bridge, discordant with normal perfusion, warranting physiologic confirmation.\nMain logical issue(s), if any: None; the vignette provides sufficient details to discriminate C as the unique best next step for assessing hemodynamic significance without assuming unstated facts.\nMain medical accuracy issue(s), if any: None; aligns with current standards where myocardial bridges can cause ischemia despite normal perfusion if flow limitation is rate-dependent, and invasive angiography with stress physiologic testing (e.g., dobutamine FFR) is recommended to guide management per cardiology guidelines, avoiding premature interventions like empiric beta-blockers, PCI (high complication risk in bridges), or surgery.\nMinimal fix: No fix needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-005", "question": "A 28-year-old woman at 36 weeks gestation presents to the ED with severe headache, visual blurring, and nausea. BP is 188/118 mm Hg, HR 96/min. She is agitated and reports seeing flashing lights. Reflexes are brisk with 3+ patellar reflexes and 1-2 beats of clonus. Labs: platelets 102,000/µL, AST 105 U/L, ALT 98 U/L, Cr 1.2 mg/dL, urine protein/Cr ratio 1.0. Shortly after arrival, she has a generalized tonic-clonic seizure lasting 90 seconds, then becomes postictal. Oxygen saturation is 95% on 2 L nasal cannula. Fetal heart monitoring is reassuring. She has already received a 4-g IV loading dose of magnesium sulfate en route. Which is the most appropriate immediate next step after stabilizing airway and breathing?", "options": ["Administer an additional 2-g IV magnesium bolus and start IV labetalol", "Start continuous propofol infusion and emergent head CT before antihypertensives", "Give IV levetiracetam, discontinue magnesium, and proceed to emergent cesarean delivery", "Start nicardipine infusion targeting BP <120/80 mm Hg and delay delivery for 48 hours", "Administer IV diazepam and begin oral labetalol once she awakens"], "answer": "A", "answer_index": 0, "explanation": "She has eclampsia with severe features; magnesium is first-line for seizure control and recurrence prevention, and a repeat bolus is appropriate after a breakthrough seizure on therapy. Rapid parenteral antihypertensive (e.g., IV labetalol) is needed to control severe BP, with expeditious delivery once stabilized. Propofol, levetiracetam alone, aggressive BP lowering to normal, or delaying delivery are not appropriate initial strategies.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 36-week gestation, severe hypertension (188/118 mm Hg), visual disturbances, brisk reflexes with clonus, thrombocytopenia (102,000/µL), elevated AST/ALT, proteinuria (urine protein/Cr 1.0), breakthrough seizure after 4-g MgSO4 load, reassuring fetal monitoring. These drive eclampsia diagnosis, requiring seizure control and BP management prior to delivery. Main logical issue(s): None; stem provides sufficient details for unique best answer without contradictions or underspecification. Main medical accuracy issue(s): None; aligns with ACOG guidelines—magnesium sulfate for eclampsia seizure prophylaxis with additional bolus for breakthrough, IV labetalol for acute severe hypertension targeting 140-160/90-100 mm Hg, followed by expeditious delivery. Minimal fix: Not needed, as item is unambiguous and accurate.\\n\\nBest-answer defensibility: a) Question asks for immediate next step in managing eclampsia with breakthrough seizure and severe hypertension. b) Discriminating findings: Recent seizure post-Mg load, persistent severe BP, no fetal distress. c) Eclampsia; prioritize recurrent seizure prevention and BP control. d) A fits: Additional 2-g Mg bolus standard for breakthrough, IV labetalol appropriate antihypertensive. e) B worse: Propofol/CT delays urgent BP control; C incorrect: Mg is preferred over levetiracetam in eclampsia, don't discontinue; D wrong: Overly aggressive BP target risks hypoperfusion, no delay in delivery; E inferior: Diazepam not first-line, oral route inappropriate acutely. Logical validity: Supports unique best (A), matches key.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 36-week gestation, severe hypertension (188/118 mm Hg), visual disturbances, brisk reflexes with clonus, thrombocytopenia (102,000/µL), elevated AST/ALT, proteinuria (urine protein/Cr 1.0), breakthrough seizure after 4-g MgSO4 load, reassuring fetal monitoring. These drive eclampsia diagnosis, requiring seizure control and BP management prior to delivery. Main logical issue(s): None; stem provides sufficient details for unique best answer without contradictions or underspecification. Main medical accuracy issue(s): None; aligns with ACOG guidelines—magnesium sulfate for eclampsia seizure prophylaxis with additional bolus for breakthrough, IV labetalol for acute severe hypertension targeting 140-160/90-100 mm Hg, followed by expeditious delivery. Minimal fix: Not needed, as item is unambiguous and accurate.\n\nBest-answer defensibility: a) Question asks for immediate next step in managing eclampsia with breakthrough seizure and severe hypertension. b) Discriminating findings: Recent seizure post-Mg load, persistent severe BP, no fetal distress. c) Eclampsia; prioritize recurrent seizure prevention and BP control. d) A fits: Additional 2-g Mg bolus standard for breakthrough, IV labetalol appropriate antihypertensive. e) B worse: Propofol/CT delays urgent BP control; C incorrect: Mg is preferred over levetiracetam in eclampsia, don't discontinue; D wrong: Overly aggressive BP target risks hypoperfusion, no delay in delivery; E inferior: Diazepam not first-line, oral route inappropriate acutely. Logical validity: Supports unique best (A), matches key.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-006", "question": "A 9-year-old boy presents with 3 months of diffuse musculoskeletal pain, morning stiffness lasting 30-45 minutes, and profound fatigue. He was previously athletic but now avoids activity due to pain. Exam shows generalized tenderness over muscles and entheses, mild limitation of lumbar flexion, and no clear joint effusions. No rash, fevers, or weight loss. Labs: CBC, ESR, CRP, CK, aldolase, and TSH are normal. ANA 1:80 speckled, RF negative, HLA-B27 negative. XR of sacroiliac joints and spine are normal. He has fragmented sleep, difficulty focusing at school, and abdominal pain without alarm features. Which strategy is most appropriate to establish the correct diagnosis and direct management?", "options": ["Order whole-body MRI to evaluate for enthesitis-related arthritis or occult malignancy", "Diagnose juvenile fibromyalgia and implement a graded exercise and CBT program", "Perform lumbar puncture and brain MRI to evaluate for CNS vasculitis", "Start a 3-month trial of NSAIDs and low-dose prednisone for suspected JIA", "Order EMG and nerve conduction studies to exclude small fiber neuropathy"], "answer": "B", "answer_index": 1, "explanation": "Chronic widespread pain, normal inflammatory and muscle markers, non-restorative sleep, cognitive complaints, and functional GI symptoms are characteristic of juvenile fibromyalgia. Early diagnosis with emphasis on graded aerobic/strength exercise and cognitive behavioral therapy is key. Whole-body MRI, CNS workup, empiric steroids, or EMG are unnecessary and potentially harmful in this presentation.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Diffuse musculoskeletal pain, morning stiffness, profound fatigue, generalized tenderness over muscles/entheses, mild lumbar flexion limitation without joint effusions, normal inflammatory/muscle markers (CBC, ESR, CRP, CK, aldolase), low-titer ANA, negative RF/HLA-B27, normal XR, plus fragmented sleep, cognitive difficulties, and functional abdominal pain without alarm features. These align with juvenile fibromyalgia criteria, emphasizing non-inflammatory, widespread pain with somatic symptoms.\\nMain logical issue(s), if any: None; stem provides sufficient discriminating details to identify fibromyalgia as the most likely diagnosis, ruling out inflammatory arthritis, malignancy, vasculitis, or neuropathy via negative findings, making B uniquely defensible.\\nMain medical accuracy issue(s), if any: None; presentation and management (graded exercise, CBT) are consistent with current pediatric rheumatology guidelines for juvenile fibromyalgia, avoiding unnecessary invasive tests or empiric steroids that could harm.\\nMinimal fix: No fix needed; item is already unambiguous and accurate, but adding 'no neurologic deficits' to stem could further strengthen exclusion of options C and E.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Diffuse musculoskeletal pain, morning stiffness, profound fatigue, generalized tenderness over muscles/entheses, mild lumbar flexion limitation without joint effusions, normal inflammatory/muscle markers (CBC, ESR, CRP, CK, aldolase), low-titer ANA, negative RF/HLA-B27, normal XR, plus fragmented sleep, cognitive difficulties, and functional abdominal pain without alarm features. These align with juvenile fibromyalgia criteria, emphasizing non-inflammatory, widespread pain with somatic symptoms.\nMain logical issue(s), if any: None; stem provides sufficient discriminating details to identify fibromyalgia as the most likely diagnosis, ruling out inflammatory arthritis, malignancy, vasculitis, or neuropathy via negative findings, making B uniquely defensible.\nMain medical accuracy issue(s), if any: None; presentation and management (graded exercise, CBT) are consistent with current pediatric rheumatology guidelines for juvenile fibromyalgia, avoiding unnecessary invasive tests or empiric steroids that could harm.\nMinimal fix: No fix needed; item is already unambiguous and accurate, but adding 'no neurologic deficits' to stem could further strengthen exclusion of options C and E.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-007", "question": "A 63-year-old woman with a 15-year history of seropositive rheumatoid arthritis (RA) presents with progressive dyspnea and dry cough over 4 months. Medications: methotrexate 20 mg weekly (for 10 years), low-dose prednisone 5 mg daily, and adalimumab for 3 years. She has no fevers or weight loss. Exam reveals bibasilar fine inspiratory crackles and mild digital clubbing. PFTs show FVC 62% predicted, FEV1/FVC 0.85, and DLCO 40% predicted. HRCT of the chest shows subpleural reticulation, traction bronchiectasis, and honeycombing predominantly in the bases, consistent with a usual interstitial pneumonia (UIP) pattern. There are no ground-glass opacities. Which is the most appropriate modification of her RA and lung disease management?", "options": ["Discontinue methotrexate permanently and increase adalimumab dose", "Continue current RA regimen and add nintedanib", "Stop adalimumab and switch to rituximab while continuing methotrexate", "Stop methotrexate and adalimumab, and start high-dose prednisone plus azathioprine", "Add mycophenolate mofetil to current regimen for treatment of ILD"], "answer": "B", "answer_index": 1, "explanation": "This is RA-associated ILD with a UIP pattern, which behaves like idiopathic pulmonary fibrosis and typically does not respond to high-dose immunosuppression. Nintedanib slows FVC decline in progressive fibrosing ILDs, including RA-ILD, and can be added while stable articular disease is controlled. Routine methotrexate cessation is not clearly beneficial here, and switching biologics or adding mycophenolate is more appropriate for inflammatory (e.g., NSIP) patterns rather than established fibrotic UIP.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 63-year-old with longstanding seropositive RA on methotrexate, adalimumab, and low-dose prednisone; progressive dyspnea and dry cough without fevers/weight loss; bibasilar crackles and clubbing; restrictive PFTs with low DLCO; HRCT showing basal-predominant UIP pattern (reticulation, traction bronchiectasis, honeycombing) without ground-glass opacities, indicating fibrotic RA-ILD behaving like IPF. These clues support continuing RA regimen for articular control while adding antifibrotic therapy, as immunosuppression is ineffective/harmful in established UIP. Main logical issue(s), if any: None; stem provides sufficient details for discrimination, with options comparable in management scope, allowing B as uniquely best without contradictions or underspecification. Main medical accuracy issue(s), if any: None; aligns with current guidelines (e.g., ATS/ERS on progressive fibrosing ILDs, INBUILD trial including RA-ILD for nintedanib efficacy in slowing FVC decline; UIP in RA-ILD typically non-responsive to intensified immunosuppression; no routine MTX cessation required in stable long-term users with fibrotic pattern). Minimal fix: Not needed, as item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 63-year-old with longstanding seropositive RA on methotrexate, adalimumab, and low-dose prednisone; progressive dyspnea and dry cough without fevers/weight loss; bibasilar crackles and clubbing; restrictive PFTs with low DLCO; HRCT showing basal-predominant UIP pattern (reticulation, traction bronchiectasis, honeycombing) without ground-glass opacities, indicating fibrotic RA-ILD behaving like IPF. These clues support continuing RA regimen for articular control while adding antifibrotic therapy, as immunosuppression is ineffective/harmful in established UIP. Main logical issue(s), if any: None; stem provides sufficient details for discrimination, with options comparable in management scope, allowing B as uniquely best without contradictions or underspecification. Main medical accuracy issue(s), if any: None; aligns with current guidelines (e.g., ATS/ERS on progressive fibrosing ILDs, INBUILD trial including RA-ILD for nintedanib efficacy in slowing FVC decline; UIP in RA-ILD typically non-responsive to intensified immunosuppression; no routine MTX cessation required in stable long-term users with fibrotic pattern). Minimal fix: Not needed, as item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-008", "question": "A 45-year-old man with poorly controlled type 2 diabetes (A1c 10.8%), BMI 36 kg/m², and mild nonproliferative diabetic retinopathy presents for follow-up. Medications: metformin 1000 mg BID and basal insulin glargine 35 units nightly. He had an episode of acute pancreatitis 3 years ago attributed to severe hypertriglyceridemia (TG 1,800 mg/dL); since then, triglycerides have been controlled around 250-300 mg/dL on fenofibrate. He drinks no alcohol. eGFR is 65 mL/min/1.73 m², AST/ALT are mildly elevated (1.5× ULN), and ultrasound shows fatty liver without biliary disease. He is interested in newer injectable therapies for weight loss and glucose control. Which glucose-lowering agent is most appropriate to add now?", "options": ["Liraglutide", "Semaglutide", "Dulaglutide", "Tirzepatide", "Empagliflozin"], "answer": "E", "answer_index": 4, "explanation": "Given prior pancreatitis, any incretin-based therapy (GLP-1 receptor agonists and dual GIP/GLP-1 agonists like tirzepatide) carries a theoretical risk of recurrence, and product labels recommend caution or avoidance. An SGLT2 inhibitor such as empagliflozin improves glycemic control, promotes modest weight loss, and provides CV/renal benefits without known pancreatitis signal. His eGFR is adequate, making empagliflozin the safest choice among the listed options.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues: Poorly controlled T2DM (A1c 10.8%), obesity (BMI 36), history of acute pancreatitis due to severe hypertriglyceridemia (now controlled at 250-300 mg/dL on fenofibrate), no alcohol, eGFR 65, mild AST/ALT elevation with fatty liver, interest in newer injectable therapies for weight loss and glucose control; on metformin and basal insulin. These drive consideration of agents balancing glycemic control, weight loss, renal benefits, and pancreatitis risk, but fail to specify priority (e.g., absolute safety vs efficacy/patient preference for injectable). Main logical issue(s): Multiple answers defensible—E (empagliflozin: safest per labels avoiding incretin pancreatitis risk, renal/CV benefits, modest weight loss, but oral not matching injectable interest) and D (tirzepatide: injectable, superior weight loss/glucose control, board-relevant for obesity/DM, but requires assuming low recurrence risk despite warning); A-C similarly defensible as D if favoring GLP-1RA, leading to ambiguity. Underspecified on whether to honor injectable request or prioritize theoretical risk. Main medical accuracy issue(s): Consistent with product labels recommending alternatives to incretins in pancreatitis history; SGLT2i appropriate for eGFR 65 and DM, but incretin-pancreatitis link is weak/postmarketing, and standard care often uses GLP-1RA/tirzepatide with monitoring; ignores superior tirzepatide weight loss in obesity. Minimal fix: Revise stem to 'Despite his interest in injectables, which agent is most appropriate considering pancreatitis history?' to prioritize safety and make E unique best.\",\n  \"medical_accuracy_score\": 3,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues: Poorly controlled T2DM (A1c 10.8%), obesity (BMI 36), history of acute pancreatitis due to severe hypertriglyceridemia (now controlled at 250-300 mg/dL on fenofibrate), no alcohol, eGFR 65, mild AST/ALT elevation with fatty liver, interest in newer injectable therapies for weight loss and glucose control; on metformin and basal insulin. These drive consideration of agents balancing glycemic control, weight loss, renal benefits, and pancreatitis risk, but fail to specify priority (e.g., absolute safety vs efficacy/patient preference for injectable). Main logical issue(s): Multiple answers defensible—E (empagliflozin: safest per labels avoiding incretin pancreatitis risk, renal/CV benefits, modest weight loss, but oral not matching injectable interest) and D (tirzepatide: injectable, superior weight loss/glucose control, board-relevant for obesity/DM, but requires assuming low recurrence risk despite warning); A-C similarly defensible as D if favoring GLP-1RA, leading to ambiguity. Underspecified on whether to honor injectable request or prioritize theoretical risk. Main medical accuracy issue(s): Consistent with product labels recommending alternatives to incretins in pancreatitis history; SGLT2i appropriate for eGFR 65 and DM, but incretin-pancreatitis link is weak/postmarketing, and standard care often uses GLP-1RA/tirzepatide with monitoring; ignores superior tirzepatide weight loss in obesity. Minimal fix: Revise stem to 'Despite his interest in injectables, which agent is most appropriate considering pancreatitis history?' to prioritize safety and make E unique best.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-009", "question": "A 27-year-old woman is brought to the ED after collapsing during a 10-km race. Bystanders report sudden loss of consciousness without seizure activity; CPR was started immediately, and an AED delivered one shock for ventricular fibrillation with ROSC. She is now awake and oriented. No drugs or supplements; family history notable for an uncle who died suddenly at 32 while swimming, presumed drowning. Vitals: HR 78/min, BP 112/68 mm Hg, normal exam. Labs and echocardiogram are normal. Baseline ECG shows QTc 460 ms, normal QRS, and normal ST-T waves. During recovery from an exercise treadmill test, she develops polymorphic VT that terminates spontaneously; QTc in recovery is 510 ms with late-appearing T waves in V2-V4. Which is the most appropriate next step in management?", "options": ["Implant an ICD and start high-dose beta-blocker therapy", "Start nadolol and schedule left cardiac sympathetic denervation", "Start flecainide in addition to beta-blocker therapy", "Begin verapamil and restrict participation to low-intensity sports", "Perform genetic testing for catecholaminergic polymorphic VT before any therapy"], "answer": "A", "answer_index": 0, "explanation": "This presentation is consistent with congenital long QT syndrome (likely LQT1 or LQT2) with exercise-associated VF arrest and marked QT prolongation in recovery. Survivors of cardiac arrest from LQTS require ICD plus beta-blocker therapy. LCSD or flecainide may be adjuncts in selected cases but not first-line over ICD after arrest. Verapamil is ineffective, and genetic testing should not delay life-saving therapy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include exercise-triggered collapse with VF arrest, family history of sudden death, baseline QTc 460 ms (prolonged), recovery QTc 510 ms with late T waves and polymorphic VT, normal echo/labs, no drugs. These point to congenital long QT syndrome (LQTS, likely type 1 or 2) as the most likely diagnosis, with cardiac arrest requiring secondary prevention. Option A (ICD implantation plus high-dose beta-blocker) aligns with guidelines for LQTS survivors of VF arrest, providing defibrillation and arrhythmia suppression. Alternatives are inferior: B (nadolol + LCSD) is adjunct for refractory cases, not first-line post-arrest; C (flecainide + beta-blocker) suits LQT3, not evident here; D (verapamil + activity restriction) is ineffective for LQTS; E (genetic testing for CPVT before therapy) misdirects to CPVT (which lacks QT prolongation) and delays intervention. No main logical issues; stem allows discrimination without contradictions or underspecification. No main medical accuracy issues; consistent with AHA/ESC guidelines on LQTS management, emphasizing ICD for secondary prevention. Minimal fix: No edit required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include exercise-triggered collapse with VF arrest, family history of sudden death, baseline QTc 460 ms (prolonged), recovery QTc 510 ms with late T waves and polymorphic VT, normal echo/labs, no drugs. These point to congenital long QT syndrome (LQTS, likely type 1 or 2) as the most likely diagnosis, with cardiac arrest requiring secondary prevention. Option A (ICD implantation plus high-dose beta-blocker) aligns with guidelines for LQTS survivors of VF arrest, providing defibrillation and arrhythmia suppression. Alternatives are inferior: B (nadolol + LCSD) is adjunct for refractory cases, not first-line post-arrest; C (flecainide + beta-blocker) suits LQT3, not evident here; D (verapamil + activity restriction) is ineffective for LQTS; E (genetic testing for CPVT before therapy) misdirects to CPVT (which lacks QT prolongation) and delays intervention. No main logical issues; stem allows discrimination without contradictions or underspecification. No main medical accuracy issues; consistent with AHA/ESC guidelines on LQTS management, emphasizing ICD for secondary prevention. Minimal fix: No edit required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-010", "question": "A 7-year-old boy with sickle cell disease (HbSS) presents with acute onset of severe left hip pain and inability to bear weight. He had a pain crisis 2 weeks ago treated with IV opioids and hydration. Temperature is 38.3°C, HR 120/min, BP 96/58 mm Hg. Hip exam reveals extreme pain with any passive motion, especially internal rotation, and the leg is slightly flexed and externally rotated. WBC 18,000/µL, CRP 14 mg/dL, ESR 86 mm/h. Plain radiograph is unremarkable. MRI of the pelvis obtained within 6 hours of symptom onset shows bone marrow edema of the femoral head and neck with a moderate hip joint effusion, but no definite abscess or cortical destruction. Which is the most appropriate next step?", "options": ["Treat as vaso-occlusive crisis with IV opioids and observe for 24-48 hours", "Start broad-spectrum IV antibiotics and schedule urgent surgical hip drainage", "Obtain radionuclide bone scan to differentiate infarction from osteomyelitis", "Repeat pelvic MRI with contrast in 72 hours before deciding on surgery", "Start IV antibiotics and aspirate the hip joint under ultrasound guidance"], "answer": "E", "answer_index": 4, "explanation": "In children with sickle cell disease, distinguishing osteomyelitis/septic arthritis from bone infarction is challenging; fever, high inflammatory markers, inability to bear weight, and effusion demand prompt evaluation. Joint aspiration with culture, ideally under ultrasound guidance, plus empiric IV antibiotics is the appropriate next step to diagnose or exclude septic arthritis early. Delaying for observation or repeat imaging risks joint destruction; bone scan is nonspecific in this setting, and immediate surgical drainage without diagnostic aspiration may be premature without frank clinical sepsis.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include acute severe hip pain with inability to bear weight, fever (38.3°C), tachycardia, elevated WBC (18,000/µL), CRP (14 mg/dL), ESR (86 mm/h), and MRI showing bone marrow edema with moderate effusion but no abscess or cortical destruction in a child with sickle cell disease (HbSS) post-recent pain crisis. These suggest possible septic arthritis or vaso-occlusive crisis/infarction, necessitating prompt differentiation to prevent joint damage. The question asks for the most appropriate next step in this scenario. Main logical issue(s): none; the stem provides sufficient details to discriminate options without contradictions or underspecification, supporting E as uniquely best for diagnostic aspiration plus empiric antibiotics. Alternatives are inferior: A risks missing infection by observing; B is overly aggressive with immediate surgery; C uses nonspecific bone scan; D delays intervention. Main medical accuracy issue(s): none; aligns with current guidelines (e.g., prompt joint aspiration in suspected pediatric septic arthritis, especially in SCD where infection mimics infarction, per IDSA and AAP standards). Minimal fix: N/A, as the item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include acute severe hip pain with inability to bear weight, fever (38.3°C), tachycardia, elevated WBC (18,000/µL), CRP (14 mg/dL), ESR (86 mm/h), and MRI showing bone marrow edema with moderate effusion but no abscess or cortical destruction in a child with sickle cell disease (HbSS) post-recent pain crisis. These suggest possible septic arthritis or vaso-occlusive crisis/infarction, necessitating prompt differentiation to prevent joint damage. The question asks for the most appropriate next step in this scenario. Main logical issue(s): none; the stem provides sufficient details to discriminate options without contradictions or underspecification, supporting E as uniquely best for diagnostic aspiration plus empiric antibiotics. Alternatives are inferior: A risks missing infection by observing; B is overly aggressive with immediate surgery; C uses nonspecific bone scan; D delays intervention. Main medical accuracy issue(s): none; aligns with current guidelines (e.g., prompt joint aspiration in suspected pediatric septic arthritis, especially in SCD where infection mimics infarction, per IDSA and AAP standards). Minimal fix: N/A, as the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]